Trial Profile
A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Walvax Biotechnology
- 11 Nov 2014 New trial record